Respiratory Microbiome in COPD and Associated Inmune Response.
- Conditions
- Pulmonary Disease (COPD), Chronic Obstructive
- Registration Number
- NCT03321708
- Lead Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- Brief Summary
Hypothesis:
COPD patients with frequent exacerbations have different pulmonary and systemic immune response than COPD patients without frequent exacerbations and this is related to their microbiome.
- Detailed Description
The objective of this project is to determine the pulmonary microbiome and its relationship with the pulmonary and systemic inmune response in COPD patients with frequent (FE) and non frequent exacerbations (NE).
1. The pulmonary immune response.
-The role of mucins, antimicrobial peptides (AMPs), Matrix metalloproteinases (MMPs) and Toll-like receptors (TLRs) as lung defense mechanisms and their possible relationship with the microbiome in COPD and FE patients.
2. The systemic immune response. -The pulmonary and blood inflammatory response and circulating bacterial products as markers of the systemic immune response.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 50
- Diagnosis of COPD according to national and international guidelines.
- Clinical stability (8 previous weeks).
- Signature of informed consent.
- Antibiotic treatment the previous 8 weeks.
- Other lung diseases.
- Active neoplasic disease.
- Terminal concomitant disease.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Relationship of pulmonary microbiome with the immune response (local and systemic). 6 months Microbiome will be determined by using 16s RNA techniques. The inmune response will be studied with ELISA kits.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Oriol Sibila Vidal
🇪🇸Barcelona, Spain